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The liver fluke Opisthorchis viverrini is a food-borne, zoonotic pathogen endemic to
Thailand and adjacent countries in Southeast Asia. The adult developmental stage
of the O. viverrini parasite excretes and secretes numerous proteins within the biliary
tract including the gall bladder. Lesions caused by the feeding activities of the liver fluke
represent wounds that undergo protracted cycles of healing and re-injury during chronic
infection, which can last for decades. Components of the excretory/secretory (ES)
complement released by the worms capably drive proliferation of bile duct epithelial cells
and are implicated in establishing the oncogenic milieu that leads to bile duct cancer,
cholangiocarcinoma. An ES protein, the secreted granulin-like growth factor termed OvGRN-1, accelerates wound resolution in mice and in vitro. To investigate angiogenesis
(blood vessel development) that may contribute to wound healing promoted by liver
fluke granulin and, by implication, to carcinogenesis during chronic opisthorchiasis, we
employed an in vitro tubule formation assay (TFA) where human umbilical vein endothelial
cells were grown on gelled basement matrix. Ten and 40 nM Ov-GRN-1 significantly
stimulated angiogenesis as monitored by cellular proliferation and by TFA in real time.
This demonstration of potent angiogenic property of Ov-GRN-1 bolsters earlier reports
on the therapeutic potential for chronic non-healing wounds of diabetics, tobacco users,
and the elderly and, in addition, showcases another of the hallmark of cancer characteristic of this carcinogenic liver fluke.
Keywords: granulin, parasite, angiogenesis, wound healing, liver cancer, human umbilical vein endothelial cells,
tubule formation assay

INTRODUCTION
Infection with the fish-borne liver flukes Opisthorchis viverrini, Opisthorchis felineus, and Clonorchis
sinensis remains a major public health problem in East Asia and Eurasia with >40 million cases. O.
viverrini is endemic in regions of Thailand, Cambodia, Lao PDR, and Vietnam (1), and opisthorchiasis has been extensively studied in Thailand where ~8 million people are infected, calculated from
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nation-wide prevalence of 9.4% for the Thai population in 2001
(2, 3). Eating undercooked fish infected with the metacercariae
stage of the fluke leads to infection in humans and other mammals, such as cats and dogs (1). The metacercarial stage of the
parasite excysts in the duodenum and the juvenile fluke migrates
into the bile ducts of the liver and matures over a month into an
adult fluke, which grazes on biliary epithelia. The parasites are
long lived, and often persist in the biliary tree for decades (1, 3).
Fluke eggs are shed into the bile and exit with the fecal stream
(1). Eggs that enter fresh water ecosystems can be ingested by the
gastropod snail Bithynia siamensis (2, 4). The parasite develops
within the snail, in turn releasing cercariae that seek out and
penetrate the skin of a cyprinid fish, which encyst in the fish as a
metacercaria, the infective stage for humans and other definitive
host species (1).
Infection causes hepatobiliary disease, including cholangitis
and periductal fibrosis (1). More problematically, both experimental and epidemiological evidence strongly implicates liver
fluke infection in the etiology of cholangiocarcinoma (CCA),
commonly known as bile duct cancer—one of the major liver
cancer subtypes (1, 5). Up to 81% of liver cancers in the endemic
Isaan region in north-eastern Thailand are CCA, which also
suffers the world’s highest incidence of CCA—65 times the
rate experienced in non-endemic regions (1, 5, 6). CCA is an
adenocarcinoma that generally exhibits slow growth and which is
diagnosed at advanced stage often with metastasis to distant sites
due to proximity to lymphatic vessels (4). Unfortunately, prognosis is dismal at the advanced stage when the primary tumor
is no longer amenable to liver resection. The mechanism(s) by
which infection initiates genetic lesions that eventually culminate
in CCA is unclear, but it likely involves biliary tract and systemic
inflammation, inflammation associated endogenous and dietary
nitrosation, and secretion of mitogens and other by the liver fluke.
One aspect of liver fluke infection that is potentially involved
in malignant transformation is the excessive, unremitting wound
healing in response to continued feeding by the parasites on
bile duct tissue (2, 3, 5). We have shown that the granulin-like
growth factor, Ov-GRN-1, secreted by the fluke is the dominant
proliferative factor and is sufficient to drive wound healing (2, 7).
A critical step in new tissue generation, including wound healing
and tumor growth induced by the infection, is the stimulation
of angiogenesis—the formation of new capillaries from preexisting blood vessels or vasculogenic stem cells (8). New tissue
requires angiogenesis to supply oxygen and nutrients, facilitate
immune surveillance, and remove waste products (9). A complex
interplay of growth factors and inhibitors regulates angiogenesis
and imbalance can lead to disease (10). While angiogenesis does
not itself initiate malignancy, it can promote tumor progression
and metastasis (9, 11). Angiogenic cytokines, including fibroblast growth factor, vascular endothelial growth factor (VEGF),
platelet-derived growth factor, and epidermal growth factor
(9, 10), stimulate endothelial cells or precursors to proliferate
and migrate, leading rapidly to new capillaries and blood vessel
networks.
The tubule formation assay (TFA) provides an informative,
convenient, rapid, and quantifiable approach to investigate
angiogenesis (12). The TFA involves endothelial cell adhesion,
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migration, proteolysis, and tubule formation by the endothelial
cells, which is initiated following seeding of the cells onto
gelled basement matrix, the natural substrate of endothelial cell
progenitors. The endothelial cells form capillary-like structures
with a lumen (12). Recombinant Ov-GRN-1 (rOv-GRN-1)
induces angiogenesis (blood vessel growth) in quail embryos in
the chorioallantoic membrane (CAM) assay (2). However, the
angiogenic potential of liver fluke granulin on human cells has
not been determined. Herein, we report potent angiogenic and
mitogenic activity of Ov-GRN-1 at nanomolar concentration
on primary human umbilical vein endothelial cells (HUVECs)
using both a high-throughput TFA with automated ImageJ-based
analyses and with the xCELLigence system real-time cell assay.

MATERIALS AND METHODS
Ov-GRN-1 Recombinant Production

Purification of rOv-GRN-1 was achieved using an AKTA10
purification system at 4°C (GE Healthcare) as previously
described (2, 13). Briefly, BL21 E. coli bacterial pellet containing
the rOv-GRN-1 expression plasmid was lysed with three freeze/
thaw cycles followed by sonication. The resulting insoluble pellet
was solubilized in urea-containing nickel binding buffer [8 M
urea/300 mM NaCl/50 mM imidazole/50 mM sodium phosphate
pH 8 (Sigma)]. The 0.22-µM-filtered supernatant was passed over
2 × 5 ml Histrap IMAC nickel columns (GE Healthcare) and
washed with increasing imidazole concentrations and eluted with
500-mM imidazole in binding buffer. Refolding of urea-denatured
rOv-GRN-1 was performed with 28 ml of G10 Sephadex resin on
a XK16/20 column (GE Healthcare) with 7 ml applied at 100 µg/
ml and eluted with 150-mM NaCl, 50-mM sodium phosphate, pH
6. A 120-ml Superdex 30 XK16/60 column (GE Healthcare) was
used to fractionate rOv-GRN-1 monomer eluting at a folded size
equivalent to ~1 kDa. Protein concentration was determined by
a combination of microplate Bradford assay (Bio-Rad) according
to the manufacturer’s instructions and optical density at 280 nm.

Human Umbilical Vein Endothelial Cells

Human umbilical vein endothelial cells pooled from donors
(PromoCell, Heidelberg, Germany) were cultured in T75 tissue
culture flasks in complete EGM-2 medium (PromoCell) at 37°C in
a humidified atmosphere in 5% CO2 in air. HUVECs were grown
to ~80% confluence, after which the culture was trypsinized using
the PromoCell Detach Kit (PromoCell). The cells investigated by
tubule formation assay (TFA) were used from the third, fourth,
or fifth passage only, with HUVEC passaged to ~80% confluence
within 24 h of the TFA, as described (14).

Proliferation xCELLigence Assay

Cells were seeded at 5,000 cells per well in 200 µl of complete
media (above) in E-plates (ACEA Biosciences, San Diego, CA,
USA) and grown overnight while monitored with an xCELLigence DP system (ACEA Biosciences) which monitors cellular
events in real time by measuring electrical impedance across
interdigitated gold micro-electrodes integrated on the bottom of
tissue culture plates. Cells were washed three times with PBS and
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were plotted and Ov-GRN-1 treatments compared to mediumalone blank control using one-way ANOVA with Holm–Sidak’s
multiple comparisons test, P ≤ 0.05 was considered to be statistically significant.

replaced with 180 µl EGM-2 basal media (no growth factors or
supplements) and incubated for a minimum of 6 h before further
treatment. Treatments were prepared at 10 × concentrations and
added to each well in a total volume of 20 µl. The xCELLigence
DP recorded cell index readings every 15 min for 3 days after
treatment. Cell index readings were normalized before treatment
and cell proliferation ratios were determined from four biological
replicates and represent the relative numbers of cells compared
to control cells. A two-way ANOVA with Holm–Sidak’s multiple
comparisons test was used to compare Ov-GRN-1 treatment to
medium-alone control, with P ≤ 0.05 deemed significant.

RESULTS
To assess the influence of Ov-GRN-1 on HUVEC compared
with other cell types, we analyzed HUVEC cellular proliferation
and migration with the xCELLigence system. Treatment with
Ov-GRN-1 induces proliferation in a range of cell types (2, 4, 17).
Exposure of HUVEC to 5–20 nM Ov-GRN-1 showed a similar
response (Figure 1). As the angiogenic assay with HUVECs would
be assessed at 12 h, for proliferation, we focused on the first 24 h
and noted minor (5–11%) non-significant increase above values

Tubule Formation Assay (TFA)

Growth factor-reduced Matrigel (Corning, Corning, NY, USA)
was plated into a 96-well μ-angiogenesis plate (ibidi, Planegg,
Germany) at 10 μl/well, and incubated at 37°C in 5% CO2 in air
for 60 min as described (14). HUVECs were detached (above)
and resuspended in complete endothelial cell growth medium
2 (EGM-2) (PromoCell), and seeded at 10,000 cells/well in
medium supplemented with 10 µM sulforaphane (SFPH, Sigma)
(negative control), 1.2 nM VEGF-165 (Novus Biologicals) (positive control), or 5, 10, 20, and 40 nM Ov-GRN-1. The ibidi plate
was incubated for 12 h in a humidified atmosphere of 5% CO2
in air at 37°C in a microscope stage top incubator (OKOLAB,
Pozzuoli, Naples, Italy). At intervals, photomicrographs of cells
and nascent and developed tubules were collected using a Leica
DMi8 automated platform microscope under bright field at
2.5 × magnification, and Leica LASX software (Leica).

Analysis of Tubule Formation

Automated angiogenesis assessment was performed on TFA
4902 pixel images by ImageJ (NIH) with the phase-contrast
Angiogenesis Analyzer plugin tool as described (12, 15). Settings
used were as follows: 10 pixel minimum object size; 25 pixel minimum branch size; 2,500 pixel artifactual loop size; 25 pixel isolated
element size threshold; 30 pixel master segment size threshold;
with iteration number of 3. The four output metrics (mesh count,
segment count, segment length, and junction count) were either
plotted directly or as a percentage relative to the medium-alone
blank treatment (treatment measure divided by medium-alone
measure). A two-way ANOVA with Holm–Sidak’s multiple comparisons test was used to compare Ov-GRN-1 treatment against
medium-alone blank control for the four metrics with P ≤ 0.05
deemed significant.
Combining the four metrics into a single evenly weighted variable was accomplished through the calculation of Z standardized
scores that were based on population values (16). The formula
below generates the Z score and represented the distance between
the raw score and the population mean in units of the SD.
Population values were estimated from 39 treatment replicates.

Figure 1 | Cell proliferation induction by Ov-GRN-1 with human umbilical
vein endothelial cells (HUVECs). (A) Normalized cell index (nCI) output of the
xCELLigence system of treatments of 5–20 nM Ov-GRN-1 on HUVECs cells
over 70 h. (B) nCI relative to medium only negative controls (0 nM Ov-GRN-1)
from (A) is plotted to highlight the first 24 h after treatment. RM two-way
ANOVA with Holm–Sidak’s multiple comparison test of Ov-GRN-1 treatment
vs medium only control at each time point: ns = not significant; *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001. Data points are average values of
four biological replicates and have been nudged ±0.2–1 h to ensure that SE
bars are visible.

Z = ( treatment metric value − metric population mean )
/populatioon standard deviation
The combined robust Z score (Z*) was generated for each
replicate from the median Z score of the four metrics. Z* scores
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of negative controls from 5 to 10 nM Ov-GRN-1 (Figure 1B).
Twenty nanomolars were sufficient to induce a significant 14%
increase in cell index from 4 h (*P < 0.05) that had expanded
to 29% by 24 h (****P < 0.0001), indicative of proliferation
(Figure 1B). Cell migration has also been reported with bile duct
cells from Ov-GRN-1 treatment (2, 3). In contrast to induction
of proliferation, our HUVEC tests with 10–100 nM Ov-GRN-1
using CIM e-plates (cell invasion and migration xCELLigence
plates) did not reveal an increase in migration compared to
controls (data not shown).
The TFA angiogenesis was used to assess the ability of rOvGRN-1 to induce capillary-like tubule structures from endothelial cells. The three main characteristics considered for angiogenic
stimulation in the TFA are highlighted in Figure 2A—tubule
“segments” branch at “junctions” and combine to enclose a
“mesh.” Ten (10) micromolar SFPH negative control revealed an
ablated tubule network, as reported in other studies (18), whereas
positive control VEGF at 1.2 nM strongly stimulated a network
of tubules compared to the medium only group (19) (Figure 2A).
The automated ImageJ angiogenesis plugin analysis measures
both topological features that represent network complexity
(meshes and branching junction points) and morphometric
descriptors that are dimensional and considered the principal
angiogenic in vitro response (tubule segment number and
total tubule segment length) (8). Ov-GRN-1 treatments show
a concentration dependent increasingly complex tubule mesh
network (Figure 2). The mesh count raw data (Figure 2C)
show that 40 nM Ov-GRN-1 increased the mesh count from the
medium only control of 9.7–15.7 meshes—a highly significant
(P < 0.0001) relative increase over the blank control of 62%
(Figure 3A). In addition, 10 and 20 nM Ov-GRN-1 increased the
mesh count to a lesser degree—35% increase (P < 0.01) and a
20% increase (non-significant), respectively. While the number
of branching junctions (Figure 3B) increased slightly (13–18%)
with 10–40 nM Ov-GRN-1 treatments, none of these changes
were significantly different to the medium only control. The
dimensional measures both showed slight increases of 8–18%
with 10–20 nM but only significant increases from 40 nM

Ov-GRN-1 treatment (Figures 3C,D). The number of tubule
segments increased by 31% (P < 0.01) and the associated total
length of the tubule segments increased by 27% (P < 0.05) to the
medium only control. The 5 nM Ov-GRN-1 treatment showed
almost no difference (non-significant minor reductions of 5–8%)
for all four metrics relative to medium only controls.
To assess the angiogenic potential of Ov-GRN-1 treatments
the four metrics were converted to Z-scores and combined into
a single median robust Z score (Z*) for each replicate (Figure 4).
The Z* score incorporates differences from the total population
mean and population variation. This dimensionless variable is
a useful equally weighted mechanism to combine metrics with
different means and variations into a single composite variable for
statistical comparisons. Comparing the Z* scores to the medium
only controls (Figure 4) showed 10–40 nM Ov-GRN-1 induced
increased angiogenesis but only 10 and 40 nM showed significant
increases (P < 0.05 and P < 0.001, respectively). As noted with
the four separate metrics, 5 nM Ov-GRN-1 did not stimulate
angiogenesis.

DISCUSSION
Angiogenesis describes the growth of new vasculature and is a
process that has been the subject of significant historical interest
due to its involvement in a spectrum of diseases (10, 20, 21). During
development new blood vessels are essential and angiogenesis is
rapid (9, 10). In the fully developed adult, as part of physiologic
processes such as wound healing, angiogenesis is turned on, but
only transiently (9, 10). Over a century ago, studies demonstrated
that the mechanisms of tumor growth and spread are intimately
linked to the formation of new blood vessels from pre-existing
larger blood vessels (10). Subsequently, it was determined that
as this process occurs, the “angiogenic switch” is almost always
activated and remains on, causing normally quiescent vasculature
to sustain expanding neoplastic growths (9).
Molecular angiogenic studies have focused on VEGF, as many
angiogenic factors induce signals that result in blood vessel signaling that ultimately rely on VEGF (10, 21, 22). Recent reports focus

Figure 2 | Angiogenic screening with primary human umbilical vein endothelial cells. Cells are seeded and treatments applied at time zero. Images are taken at
12 h and assessed in ImageJ for angiogenic properties. (A) Representative images depict the control treatments at 50× magnification: medium only; anti-angiogenic
negative control [10 µM sulfurophane (SFPH)]; pro-angiogenic positive control [1.2 nM vascular endothelial growth factor (VEGF)]. The VEGF zoom overlay shows
the boxed VEGF section magnified with angiogenic features overlaid: A mesh (blue) is bordered by four tubule segments (red dotted lines) that join at four branching
junctions (green circles). (B) Representative images of 5–40 nM Ov-GRN-1 treatments at 50× magnification. (C) Automated mesh count quantitation of control and
Ov-GRN-1 treatments represent network complexity. The mean is marked as a horizontal bar with SE bars from 3 to 9 biological replicates plotted as circles.
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Figure 3 | Angiogenic metrics from Ov-GRN-1 treatments. ImageJ was used to quantify 12-h time point images for various characteristics of the tubule networks.
Treatments consist of the blank control (medium only); anti-angiogenic negative control [10 µM sulforaphane (SFPH)]; pro-angiogenic positive control [1.2 nM
vascular endothelial growth factor (VEGF)]; and 5–40 nM Ov-GRN-1 treatments and are plotted relative to the blank (medium only) control treatment. (A) Topological
features representing an increase in complexity of the tubule network are measured by the relative number of meshes and (B) branching junctions. (C) Dimensional
descriptors of the networked tubules include the number of tubule segments and (D) the total combined length of the tubule segments. All panels: two-way ANOVA
with Holm–Sidak’s multiple comparisons test to compare Ov-GRN-1 treatment to medium only blank control: ns = not significant; *P < 0.05; **P < 0.01;
****P < 0.0001. The mean is marked as a horizontal bar with SE bars from 3 to 9 biological replicates plotted as circles. Dotted line crosses the medium only blank
100% value.

on angiogenic signaling via VEGF-independent mechanisms
and associated problems with VEGF inhibitors for cancer treatments (23–26). One such alternate pathway that is not blocked by
VEGF inhibitors is driven by human progranulin, a growth factor
comprised of 7.5 granulin active domains (24, 27). The individual
human granulin units are difficult to produce actively (28) but
Ov-GRN-1 is produced by liver flukes as a single unit, and is
bioactive when purified from denatured bacterial recombinant
expression systems and refolded (17). Previously, we have shown
that Ov-GRN-1 is a potent growth factor that stimulates human
cell proliferation, migration, avian angiogenesis, and ultimately
mouse wound healing (3, 4, 7, 17). Ongoing research suggests
the potential for beneficial therapies emanating from pathophysiological investigation of granulins, including anti-tumor action
and promotion of wound healing (7, 29, 30).
The avian CAM assay is an informative in vivo model of
angiogenesis (31). The CAM assay is based around blood vessel
induction in avian embryos and results may not traverse phylogenetic boundaries and apply to mammalian systems. With this
consideration ensuring the parasite growth factor Ov-GRN-1
stimulated human angiogenesis is a useful step toward developing
therapeutics (2, 7, 10, 32). Herein, we focused on angiogenesis
screening using HUVEC and the tubule formation assay (TFA)
with automated imaging in real time (14). The TFA involves a

Figure 4 | Angiogenic induction from Ov-GRN-1 treatments. Converting
the four angiogenic metrics (meshes, junctions, segments, and segment
length) to dimensionless Z-scores allows a pooled median value for each
replicate (Z* score) to be generated. This enables the total angiogenic effect
to be compared between groups. One-way ANOVA with Holm–Sidak’s
multiple comparisons test to compare Ov-GRN-1 treatment to medium only
blank control: ns = not significant; *P < 0.05; **P < 0.01; ***P < 0.001. The
mean is marked as a horizontal bar with SE bars from 3 to 9 biological
replicates plotted as circles. Dotted line crosses the medium only blank
−0.28 Z* score.
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range of the angiogenic processes that includes endothelial cell
adhesion, migration, protease activity, and tubule formation (14).
The advantages of the TFA to study angiogenesis are the ease of
set up, short culture period, the ability to produce quantitative
data, and its ease of adaptation toward high-throughput analysis.
The automated TFA analysis allows comparison of both topological features that represent network complexity and morphometric dimensional descriptors that are considered the principal
angiogenic in vitro response (8). This depth of analysis combined
with the high-throughput capability allows a greater range of
treatments to be tested than the labor-intensive and subjectively
scored CAM assay.
Human liver epithelial cells (H69 bile duct cell line)
hyper-proliferates at Ov-GRN-1 concentrations of 12 nM and
above (7). Although the cell types were different, we note that
Ov-GRN-1 is able to stimulate significant HUVEC proliferation
and angiogenic stimulation at similar concentrations of at least
20 nM and 10 nM, respectively (Figures 1 and 4). Sample limitations restricted the Ov-GRN-1 TFA maximum concentration to
40 nM, but as the trend appeared to be dose dependent we predict
that higher concentration would induce further angiogenesis,
and plan to assess in the future. Mesh counts showed the most
marked rise with a 62% highly significant increase (P < 0.0001)
with 40 nM Ov-GRN-1, whereas the junction counts trended up
(13–18%) but did not reach statistical significance (Figure 3).
Whether the outcome related to the Ov-GRN-1 mechanism is
not clear, but these phenomena may be an artifact of the TFA
mechanics. A junction is the end point of at least three segments,
and more may radiate from the connecting junction. Increased
junction branching was evident with 40 nM Ov-GRN-1, a small
increase in junctions (18%) but about double the increase in
tubule segments (31%) was observed. The increase in segments
can in turn enhance the mesh count, as a single segment tubule
can grow across a mesh and split it into two smaller meshes;
our estimated mesh numbers increased 62%. To explore this
junction/mesh outcome further and delve into the angiogenic
activity of Ov-GRN-1, we plan to test other aspects of angiogenesis, including apoptosis, and to employ three-dimensional
cell culture systems that more closely reflect the in vivo situation
(19, 33). Furthermore, future studies will explore the Ov-GRN-1
proliferative and signaling responses of HUVECs to compare with
our previous work (2) that showed the transcriptional responses
of Ov-GRN-1 treatment on the H69 bile duct cell line. The most
relevant to Ov-GRN-1 transcriptional response to angiogenesis
we observed in the H69 cells was the stimulation of CXCL1, 2, 5,

and 8—chemokines that signal through CXCR2, a receptor with
complex signaling interactions but often resulting in angiogenesis
among other outcomes such as inflammation (22, 34).
Whereas the origin of helminth and host cell communication
is unknown, the process likely evolved to facilitate parasitism
(35). Metabolites participating in communication signaling may,
however, contribute to carcinogenesis (1, 35). The close homo
logy between liver fluke and human granulins may enable secreted
Ov-GRN-1 to activate signaling pathways that promote angiogenesis and wound repair of bile ducts damaged by the activities
of the parasite (4). The stimulation of wound healing potentially
evolved for successful parasitism and a concomitant productive
host–parasite relationship (2, 7). Other helminth parasites release
mediators that promote angiogenesis, and from an evolutionary
perspective, Opisthorchis-induced neovascularization may be
beneficial to parasitism (35, 36). However, given that angiogenesis represents a hallmark of cancer, the angiogenic potency of
Ov-GRN-1 may also contribute to liver fluke infection-induced
malignancy (2, 30, 35).
The current findings confirmed potent angiogenic signaling
of liver fluke with nanomolar levels of granulin and expand upon
previous reports using an in vivo CAM assay (2). Liver fluke
granulin likely contributes to the carcinogenicity of liver fluke
infection in the human biliary tract (2, 35, 36). On the other hand,
it also holds marked potential as a therapeutic wound-healing
agent and as a vaccine against the liver fluke infection-induced
cancer (2, 7, 35).
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